Global Therapeutic Peptide APIs Market Outlook and Growth Opportunities 2025

Summary

According to APO Research, the global Therapeutic Peptide APIs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Therapeutic Peptide APIs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Therapeutic Peptide APIs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Therapeutic Peptide APIs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Therapeutic Peptide APIs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Therapeutic Peptide APIs market include AmbioPharm, Aspen API, Bachem, Bio Basic, CordenPharma, CPC Scientific, GenScript, JPT Peptide Technologies and Limitless Biotech, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Therapeutic Peptide APIs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Therapeutic Peptide APIs, also provides the sales of main regions and countries. Of the upcoming market potential for Therapeutic Peptide APIs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Therapeutic Peptide APIs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Therapeutic Peptide APIs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Therapeutic Peptide APIs sales, projected growth trends, production technology, application and end-user industry.


Therapeutic Peptide APIs Segment by Company


AmbioPharm

Aspen API

Bachem

Bio Basic

CordenPharma

CPC Scientific

GenScript

JPT Peptide Technologies

Limitless Biotech

Lonza

Piramal Pharma

PolyPeptide

ScinoPharm

Syngene

USV Peptides

Hybio Pharmaceutical

Guangdong Jianyuan Pharmaceutical

Jiangsu Sinopep-Allsino Biopharmaceutical

Zhejiang Peptites Biotech

Cheng Du Sheng Nuo Biotec

Hainan Shuangcheng Pharmaceuticals

Therapeutic Peptide APIs Segment by Type


Bioactive Peptides

Synthetic Peptides

Therapeutic Peptide APIs Segment by Application


Pharmaceuticals

Scientific Research

Other

Therapeutic Peptide APIs Segment by Region


North America


United States

Canada

Europe


Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific


China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America


Brazil

Argentina

Chile

Middle East & Africa


Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Therapeutic Peptide APIs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Therapeutic Peptide APIs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Therapeutic Peptide APIs significant trends, drivers, influence factors in global and regions.
6. To analyze Therapeutic Peptide APIs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Therapeutic Peptide APIs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Therapeutic Peptide APIs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Therapeutic Peptide APIs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Therapeutic Peptide APIs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Therapeutic Peptide APIs industry.
Chapter 3: Detailed analysis of Therapeutic Peptide APIs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Therapeutic Peptide APIs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Therapeutic Peptide APIs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Therapeutic Peptide APIs Sales Value (2020-2031)
1.2.2 Global Therapeutic Peptide APIs Sales Volume (2020-2031)
1.2.3 Global Therapeutic Peptide APIs Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Therapeutic Peptide APIs Market Dynamics
2.1 Therapeutic Peptide APIs Industry Trends
2.2 Therapeutic Peptide APIs Industry Drivers
2.3 Therapeutic Peptide APIs Industry Opportunities and Challenges
2.4 Therapeutic Peptide APIs Industry Restraints
3 Therapeutic Peptide APIs Market by Company
3.1 Global Therapeutic Peptide APIs Company Revenue Ranking in 2024
3.2 Global Therapeutic Peptide APIs Revenue by Company (2020-2025)
3.3 Global Therapeutic Peptide APIs Sales Volume by Company (2020-2025)
3.4 Global Therapeutic Peptide APIs Average Price by Company (2020-2025)
3.5 Global Therapeutic Peptide APIs Company Ranking (2023-2025)
3.6 Global Therapeutic Peptide APIs Company Manufacturing Base and Headquarters
3.7 Global Therapeutic Peptide APIs Company Product Type and Application
3.8 Global Therapeutic Peptide APIs Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Therapeutic Peptide APIs Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Therapeutic Peptide APIs Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Therapeutic Peptide APIs Market by Type
4.1 Therapeutic Peptide APIs Type Introduction
4.1.1 Bioactive Peptides
4.1.2 Synthetic Peptides
4.2 Global Therapeutic Peptide APIs Sales Volume by Type
4.2.1 Global Therapeutic Peptide APIs Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Therapeutic Peptide APIs Sales Volume by Type (2020-2031)
4.2.3 Global Therapeutic Peptide APIs Sales Volume Share by Type (2020-2031)
4.3 Global Therapeutic Peptide APIs Sales Value by Type
4.3.1 Global Therapeutic Peptide APIs Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Therapeutic Peptide APIs Sales Value by Type (2020-2031)
4.3.3 Global Therapeutic Peptide APIs Sales Value Share by Type (2020-2031)
5 Therapeutic Peptide APIs Market by Application
5.1 Therapeutic Peptide APIs Application Introduction
5.1.1 Pharmaceuticals
5.1.2 Scientific Research
5.1.3 Other
5.2 Global Therapeutic Peptide APIs Sales Volume by Application
5.2.1 Global Therapeutic Peptide APIs Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Therapeutic Peptide APIs Sales Volume by Application (2020-2031)
5.2.3 Global Therapeutic Peptide APIs Sales Volume Share by Application (2020-2031)
5.3 Global Therapeutic Peptide APIs Sales Value by Application
5.3.1 Global Therapeutic Peptide APIs Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Therapeutic Peptide APIs Sales Value by Application (2020-2031)
5.3.3 Global Therapeutic Peptide APIs Sales Value Share by Application (2020-2031)
6 Therapeutic Peptide APIs Regional Sales and Value Analysis
6.1 Global Therapeutic Peptide APIs Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Therapeutic Peptide APIs Sales by Region (2020-2031)
6.2.1 Global Therapeutic Peptide APIs Sales by Region: 2020-2025
6.2.2 Global Therapeutic Peptide APIs Sales by Region (2026-2031)
6.3 Global Therapeutic Peptide APIs Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Therapeutic Peptide APIs Sales Value by Region (2020-2031)
6.4.1 Global Therapeutic Peptide APIs Sales Value by Region: 2020-2025
6.4.2 Global Therapeutic Peptide APIs Sales Value by Region (2026-2031)
6.5 Global Therapeutic Peptide APIs Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Therapeutic Peptide APIs Sales Value (2020-2031)
6.6.2 North America Therapeutic Peptide APIs Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Therapeutic Peptide APIs Sales Value (2020-2031)
6.7.2 Europe Therapeutic Peptide APIs Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Therapeutic Peptide APIs Sales Value (2020-2031)
6.8.2 Asia-Pacific Therapeutic Peptide APIs Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Therapeutic Peptide APIs Sales Value (2020-2031)
6.9.2 South America Therapeutic Peptide APIs Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Therapeutic Peptide APIs Sales Value (2020-2031)
6.10.2 Middle East & Africa Therapeutic Peptide APIs Sales Value Share by Country, 2024 VS 2031
7 Therapeutic Peptide APIs Country-level Sales and Value Analysis
7.1 Global Therapeutic Peptide APIs Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Therapeutic Peptide APIs Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Therapeutic Peptide APIs Sales by Country (2020-2031)
7.3.1 Global Therapeutic Peptide APIs Sales by Country (2020-2025)
7.3.2 Global Therapeutic Peptide APIs Sales by Country (2026-2031)
7.4 Global Therapeutic Peptide APIs Sales Value by Country (2020-2031)
7.4.1 Global Therapeutic Peptide APIs Sales Value by Country (2020-2025)
7.4.2 Global Therapeutic Peptide APIs Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.5.2 USA Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.6.2 Canada Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.8.2 Germany Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.9.2 France Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.9.3 France Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.11.2 Italy Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.12.2 Spain Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.13.2 Russia Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.16.2 China Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.16.3 China Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.17.2 Japan Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.19.2 India Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.19.3 India Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.20.2 Australia Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.24.2 Chile Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.26.2 Peru Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.28.2 Israel Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.29.2 UAE Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.31.2 Iran Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Therapeutic Peptide APIs Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Therapeutic Peptide APIs Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Therapeutic Peptide APIs Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 AmbioPharm
8.1.1 AmbioPharm Comapny Information
8.1.2 AmbioPharm Business Overview
8.1.3 AmbioPharm Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.1.4 AmbioPharm Therapeutic Peptide APIs Product Portfolio
8.1.5 AmbioPharm Recent Developments
8.2 Aspen API
8.2.1 Aspen API Comapny Information
8.2.2 Aspen API Business Overview
8.2.3 Aspen API Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.2.4 Aspen API Therapeutic Peptide APIs Product Portfolio
8.2.5 Aspen API Recent Developments
8.3 Bachem
8.3.1 Bachem Comapny Information
8.3.2 Bachem Business Overview
8.3.3 Bachem Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.3.4 Bachem Therapeutic Peptide APIs Product Portfolio
8.3.5 Bachem Recent Developments
8.4 Bio Basic
8.4.1 Bio Basic Comapny Information
8.4.2 Bio Basic Business Overview
8.4.3 Bio Basic Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.4.4 Bio Basic Therapeutic Peptide APIs Product Portfolio
8.4.5 Bio Basic Recent Developments
8.5 CordenPharma
8.5.1 CordenPharma Comapny Information
8.5.2 CordenPharma Business Overview
8.5.3 CordenPharma Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.5.4 CordenPharma Therapeutic Peptide APIs Product Portfolio
8.5.5 CordenPharma Recent Developments
8.6 CPC Scientific
8.6.1 CPC Scientific Comapny Information
8.6.2 CPC Scientific Business Overview
8.6.3 CPC Scientific Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.6.4 CPC Scientific Therapeutic Peptide APIs Product Portfolio
8.6.5 CPC Scientific Recent Developments
8.7 GenScript
8.7.1 GenScript Comapny Information
8.7.2 GenScript Business Overview
8.7.3 GenScript Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.7.4 GenScript Therapeutic Peptide APIs Product Portfolio
8.7.5 GenScript Recent Developments
8.8 JPT Peptide Technologies
8.8.1 JPT Peptide Technologies Comapny Information
8.8.2 JPT Peptide Technologies Business Overview
8.8.3 JPT Peptide Technologies Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.8.4 JPT Peptide Technologies Therapeutic Peptide APIs Product Portfolio
8.8.5 JPT Peptide Technologies Recent Developments
8.9 Limitless Biotech
8.9.1 Limitless Biotech Comapny Information
8.9.2 Limitless Biotech Business Overview
8.9.3 Limitless Biotech Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.9.4 Limitless Biotech Therapeutic Peptide APIs Product Portfolio
8.9.5 Limitless Biotech Recent Developments
8.10 Lonza
8.10.1 Lonza Comapny Information
8.10.2 Lonza Business Overview
8.10.3 Lonza Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.10.4 Lonza Therapeutic Peptide APIs Product Portfolio
8.10.5 Lonza Recent Developments
8.11 Piramal Pharma
8.11.1 Piramal Pharma Comapny Information
8.11.2 Piramal Pharma Business Overview
8.11.3 Piramal Pharma Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.11.4 Piramal Pharma Therapeutic Peptide APIs Product Portfolio
8.11.5 Piramal Pharma Recent Developments
8.12 PolyPeptide
8.12.1 PolyPeptide Comapny Information
8.12.2 PolyPeptide Business Overview
8.12.3 PolyPeptide Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.12.4 PolyPeptide Therapeutic Peptide APIs Product Portfolio
8.12.5 PolyPeptide Recent Developments
8.13 ScinoPharm
8.13.1 ScinoPharm Comapny Information
8.13.2 ScinoPharm Business Overview
8.13.3 ScinoPharm Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.13.4 ScinoPharm Therapeutic Peptide APIs Product Portfolio
8.13.5 ScinoPharm Recent Developments
8.14 Syngene
8.14.1 Syngene Comapny Information
8.14.2 Syngene Business Overview
8.14.3 Syngene Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.14.4 Syngene Therapeutic Peptide APIs Product Portfolio
8.14.5 Syngene Recent Developments
8.15 USV Peptides
8.15.1 USV Peptides Comapny Information
8.15.2 USV Peptides Business Overview
8.15.3 USV Peptides Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.15.4 USV Peptides Therapeutic Peptide APIs Product Portfolio
8.15.5 USV Peptides Recent Developments
8.16 Hybio Pharmaceutical
8.16.1 Hybio Pharmaceutical Comapny Information
8.16.2 Hybio Pharmaceutical Business Overview
8.16.3 Hybio Pharmaceutical Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.16.4 Hybio Pharmaceutical Therapeutic Peptide APIs Product Portfolio
8.16.5 Hybio Pharmaceutical Recent Developments
8.17 Guangdong Jianyuan Pharmaceutical
8.17.1 Guangdong Jianyuan Pharmaceutical Comapny Information
8.17.2 Guangdong Jianyuan Pharmaceutical Business Overview
8.17.3 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.17.4 Guangdong Jianyuan Pharmaceutical Therapeutic Peptide APIs Product Portfolio
8.17.5 Guangdong Jianyuan Pharmaceutical Recent Developments
8.18 Jiangsu Sinopep-Allsino Biopharmaceutical
8.18.1 Jiangsu Sinopep-Allsino Biopharmaceutical Comapny Information
8.18.2 Jiangsu Sinopep-Allsino Biopharmaceutical Business Overview
8.18.3 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.18.4 Jiangsu Sinopep-Allsino Biopharmaceutical Therapeutic Peptide APIs Product Portfolio
8.18.5 Jiangsu Sinopep-Allsino Biopharmaceutical Recent Developments
8.19 Zhejiang Peptites Biotech
8.19.1 Zhejiang Peptites Biotech Comapny Information
8.19.2 Zhejiang Peptites Biotech Business Overview
8.19.3 Zhejiang Peptites Biotech Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.19.4 Zhejiang Peptites Biotech Therapeutic Peptide APIs Product Portfolio
8.19.5 Zhejiang Peptites Biotech Recent Developments
8.20 Cheng Du Sheng Nuo Biotec
8.20.1 Cheng Du Sheng Nuo Biotec Comapny Information
8.20.2 Cheng Du Sheng Nuo Biotec Business Overview
8.20.3 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.20.4 Cheng Du Sheng Nuo Biotec Therapeutic Peptide APIs Product Portfolio
8.20.5 Cheng Du Sheng Nuo Biotec Recent Developments
8.21 Hainan Shuangcheng Pharmaceuticals
8.21.1 Hainan Shuangcheng Pharmaceuticals Comapny Information
8.21.2 Hainan Shuangcheng Pharmaceuticals Business Overview
8.21.3 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Sales, Value and Gross Margin (2020-2025)
8.21.4 Hainan Shuangcheng Pharmaceuticals Therapeutic Peptide APIs Product Portfolio
8.21.5 Hainan Shuangcheng Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Therapeutic Peptide APIs Value Chain Analysis
9.1.1 Therapeutic Peptide APIs Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Therapeutic Peptide APIs Sales Mode & Process
9.2 Therapeutic Peptide APIs Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Therapeutic Peptide APIs Distributors
9.2.3 Therapeutic Peptide APIs Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings